dna-evaluation-of-fragments-for-early-interception

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study) (Protocol # DELFI L-101) (NCT04825834)

The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.

Learn More


Principal Investigator(s)

Michael Bernstein, MD

Sponsor(s)

Veracyte, Inc

Contact

Carolina Garavito at 203-358-8879 or [email protected]

Location

SHMG- Pulmonary Associates
29 Hospital Plaza
Stamford, CT 06902

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.